

Patient Agreement to Systemic Therapy: Consent Form	
Bevacizumab + Oxaliplatin Modified de Gramont (Folfox)	
Patient's details / addressograph:	<input type="checkbox"/> Male <input type="checkbox"/> Female
	Special requirements (e.g. other language/other communication method)
	Consultant:

Name of proposed course of treatment: Bevacizumab + Oxaliplatin Modified de Gramont (Folfox)

Bevacizumab, Oxaliplatin and Calcium folinate IV infusions on day 1

Fluorouracil IV bolus injection on day 1, followed by Fluorouracil continuous infusion over 46 hours in a portable infusion device, also starting on day 1

All repeated every 2 weeks for 6 to 12 cycles

Macmillan leaflet(s) given

Statement of health professional (to be filled in by health professional with appropriate knowledge of proposed procedure, as specified in consent policy)

I have discussed what the treatment is likely to involve (including inpatient / outpatient treatment, timing of the treatment, follow-up appointments) and location.

The intended benefits

- Curative – to give you the best possible chance of being cured
- Palliative – the aim is not to cure but to control or shrink the disease. The aim is to improve both quality of life and survival
- Adjuvant – therapy given after surgery to reduce the risk of recurrence of cancer
- Neo-adjuvant – therapy given before surgery or radiotherapy to shrink the cancer

Significant, unavoidable or frequently occurring risks:

Common side-effects: increased bruising and bleeding, anaemia (low number of red blood cells), numbness or tingling in hands or feet particularly related to the cold / touching cold objects, feeling sick (nausea) and being sick (vomiting), tiredness, sore mouth and ulcers, taste changes, diarrhoea, high blood pressure, protein in the urine.

Less common but potentially life threatening side-effects: allergic reaction to oxaliplatin, chest pain or angina, reduced resistance to infection which can lead to a potentially fatal blood infection, gastro-intestinal perforation or fistula, increased risk of stroke or heart attack.

Other less common side-effects include: nail changes, sensitivity of the skin to sunlight, soreness and redness of the palms of the hand and soles of the feet, hair loss, watery or sore eyes, delay in wound healing. Oxaliplatin may temporarily affect the area around the voice box, which may give the sensation of not being able to catch your breath.

Very rare (less than 0.1%) cases of reversible encephalopathy with seizures, headache, altered mental status and visual disturbances have been described with bevacizumab.

If oxaliplatin accidentally leaks outside the vein during administration, it can cause damage to the surrounding tissues, including potential long-term damage to both the function and appearance of the area. This is not common, but if it happens, nursing staff are trained to minimise the risks of longer term damage.

Cancer can increase your risk of developing a blood clot (thrombosis), and having chemotherapy may increase this risk further. A blood clot may cause pain, redness and swelling in a leg or arm, or breathlessness and chest pain - you must tell your doctor straight away if you have any of these symptoms.

Some chemotherapy drugs can damage women's ovaries and men's sperm, with risk of infertility and early menopause in women. I have warned the patient about the likelihood of:

- early menopause in women infertility (in men and in women)

Some chemotherapy drugs may damage the development of a baby in the womb (foetus), leading to the many risks associated with an abnormal pregnancy. Therefore, I have discussed the issues of protected sex. This is an issue for both men and women. The patient has been advised not to become pregnant / not to get a partner pregnant during the period of treatment, and for 12 months (women) / 6 months (men) after treatment has completed.

Any other risks:

Clinician Signature

Signed..... Date

Full Name (print) / Job Title.....
(Forename) (Surname)

Statement of patient

Patient Signature

Please read this form carefully, which describes the benefits and risks of the proposed treatment. You have the right to change your mind at any time, including after you have signed this form.

I agree to undergo chemotherapy. I understand the treatment and am aware of the potential side-effects arising from this treatment.

I understand that you cannot give me a guarantee that a particular person will perform the procedure. The person will, however, have appropriate training and experience.

Signed..... Name.....

Date.....

A witness should sign below if the patient is unable to sign but has indicated his or her consent.

Signature Date

Name (PRINT)

Statement of interpreter (where appropriate)

I have interpreted the information above to the patient to the best of my ability and in a way in which I believe s/he can understand.

Signed Name (PRINT) Date.....

Confirmation of consent (to be completed by the chemotherapy nurse when the patient attends for the first cycle)

On behalf of the team treating the patient, I have confirmed with the patient that s/he has no further questions and wishes the treatment to go ahead.

Signed Name (PRINT) Date.....

Copy accepted by patient: yes/no (please ring)

Copy to be retained in patient's notes

Reason for Update: N/A	Checked and approved by Consultant: Dr T Dhillon
Version: 1	Date: 12.8.15